-
Pretzel Therapeutics Receives UK Regulatory Authorization to Advance PX578 Into Clinical Development in Patients for the Treatment of POLG-Mediated Primary Mitochondrial Disorders
-
Pretzel Therapeutics Receives FDA Fast Track Designation for PX578 for the Treatment of POLG-mediated Primary Mitochondrial Disorders
-
Mighty Therapeutics Partners with the POLG Foundation to Develop Novel Preclinical Model for POLG Mitochondrial Disorders and Parkinson’s Disease
-
Mighty Therapeutics to Develop MYTX-255 for Fatty Acid Oxidation Disorders.
-
First-Ever Mitochondrial Disease Advocacy Coalition Launched,Uniting 17 Groups Behind a Single Voice on Capitol Hill
-
Pretzel Therapeutics Advances PX578 into Phase 2 Study in Individuals Living with POLG-mediated Primary Mitochondrial Disease Following FDA Clearance of IND
-
Khondrion Announces First Patient Dosed in Pivotal Phase 3 KHENERFIN Study of Sonlicromanol in Mitochondrial DNA 3243A>G Primary Mitochondrial Disease
-
Navigating the FDA’s Complete Response Letter and identifying a path forwardfor SL1009 (DCA).
-
FDA Approval of KYGEVVI Marks a Defining Moment for Mitochondrial Disease Community and Families Affected by TK2d
